Hainan Haiyao Co., Ltd.

$ 3.77 -0.26 %

Hainan Haiyao Co., Ltd. is a pharmaceutical and medical device company with a global presence, engaged in both the production and distribution of its offerings. The company's comprehensive research and development efforts span a wide array of products, from intermediates and active pharmaceutical ingredients (APIs) to innovative chemical drugs, modern traditional Chinese medicines, biological therapeutics, cellular immunity treatments, and high-end medical devices. These offerings are presented in numerous formulations, including pills, tablets, granules, liquid extracts, powders, syrups, soft capsules, and injectable solutions, as well as health foods. Their therapeutic applications cover vital areas such as antibiotics, gastrointestinal health, and anti-tumor treatments, in addition to specialized medical technologies like cochlear implants. A notable product is Vitamin C for injection, prescribed for conditions including scurvy and idiopathic methemoglobinemia. Beyond its product lines, the firm also provides internet-based medical treatment and other healthcare services. Established in 1965, Hainan Haiyao Co., Ltd. maintains its corporate headquarters in Haikou, China.

CEO: Rongyi Xu - https://www.haiyao.com.cn

Price objectif

-

Recommandation

-

DCF

$ -14.09

Loading data...

000566.SZ vs S&P500

Loading data...

No data available.

Quick ratio

0.28

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

-11.09

may indicate that the company is undervalued or has poor growth prospects.

EPS

-0.34

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-239.72 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-12.64 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

5.59

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

585.82

means it relies more on debt, which can increase financial risk.

Free cash flow per share

-0.03

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

-20.76 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
4 indicates moderate financial health
Altman score
-1.03 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.11 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.45 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.